This study explored hospital pharmacists' perspectives about optimising statin therapy in older inpatients in Australia. An anonymous questionnaire using standardised questions in the form of five-point Likert scales to capture pharmacists' attitudes toward their role in statin optimisation, compliance of statin therapy with existing guidelines, knowledge of statin-related side effects and clinical recommendations such as starting and ceasing or deprescribing therapy, was administered. A total of 108 hospital pharmacists across Australia completed the questionnaire. Over 90% of hospital pharmacists agreed that they had an important role in managing statin therapy in older inpatients (95% CI: 90.5-98.8%). Less than 40% agreed that statin therapy in older adults was prescribed in accordance with Australian clinical guidelines (95% CI: 27.4-47.6%), and over 90% agreed that there was a need for statin deprescribing guidelines for older adults (95% CI: 85.7-97.6%). Hospital pharmacists believe that they have an important role in optimising statin therapy.
BACKGROUND
Statins are one of the most common medications used, with over 40% of all Australians over the age of 65 taking a statin. 1 Despite having guidelines in place, studies conducted to date have consistently found significant rates of over-treatment and under-treatment with statins in older people. In a survey of general practitioners' medical records in the United Kingdom, it was found that 23% of adults aged 75 years or older with no history of cardiovascular disease were prescribed statins. 2 Ensuring appropriate statin use in older people (≥ 65 years of age) is challenging due to limited clinical trial data supporting initiation, continuation or cessation of statin therapy in a population with multi-morbidity and polypharmacy. In particular, there is limited data to support statin use for the indication of primary prevention and among very old patients. 3 However, there is now evidence to support the safety of cessation or deprescribing of statins in patients with limited life expectancy. 4 Optimising statin therapy in older patients with multi-morbidity and polypharmacy regimens may require efforts from a multi-disciplinary team involving physicians, pharmacists and other relevant healthcare professionals. 5 In many Australian hospitals, pharmacists can be assigned full time to a ward where they work in a multi-disciplinary team and regularly engage in inpatient medication management. This makes them well positioned to make clinical recommendations to practitioners regarding an individual's therapy. However, there is little data looking into pharmacists' attitudes about their involvement in optimising statin use, such as dosage changes, monitoring adverse drug reactions, and recommending withdrawal in this age group. The objective of this study was to assess hospital pharmacists' perspectives and attitudes on their roles in optimising statin therapy for older inpatients.
METHOD
Hospital pharmacists' perceptions regarding statin therapy in older inpatients were captured using an anonymous, self-administered questionnaire using a five-point Likert scale (strongly agree, agree, unsure, disagree and strongly disagree). Questions were developed, reviewed and piloted by all investigators for content validity. The questionnaire captured pharmacists' socio-demographic data, as well as attitudes and beliefs on the role of pharmacists in managing statin therapy, knowledge of statinrelated side effects, and optimising statin therapy in older patients. An online version of the questionnaire was developed using the REDCap electronic data capture tools hosted at the University of Sydney, Australia. An advertisement with a link to the survey was distributed through The Society of Hospital Pharmacists of Australia (SHPA) electronic newsletter. Additionally, hard copies of the questionnaire were distributed to pharmacists at a large Sydney teaching hospital. Responses with fewer than 7 of the 13 Likert-scale questions completed were not included in the final analyses. Ethics approval was granted by the Northern Local Health District Human Research Ethics Committee (Ethics approval number: LNR/15/HAW KE/277).
Statistical Analysis
Data were entered, coded and analysed using the SPSS Statistics version 22.0 for Windows (SPSS Inc., Chicago, IL, USA), and continuous data were tested for normality using the Shapiro-Wilk test. Descriptive statistics were used to summarise the baseline characteristics of the pharmacist population. Means with standard deviations (SD), medians with an interquartile range (IQR), or proportions were reported where appropriate. Percentage agreement with 95% confidence intervals (95% CIs) were calculated by grouping responses 'strongly agree' and 'agree' together, with the remaining responses representing 'unsure', 'disagree' and 'strongly disagree'. Associations between pharmacist characteristics, such as years of practice and attitudes toward optimising statin therapy were assessed using Spearman's rank correlation. Associations between gender, home medicine review accreditation status, area and sector of practice and attitudes toward optimising statin therapy were assessed using the Mann-Whitney U-test. Relationships between pharmacy position or qualifications and responses were assessed using the Kruskal-Wallis test.
RESULTS
Electronic surveys were advertised to approximately 3000 pharmacists in Australia through an SHPA newsletter, and 20 hard copy surveys were distributed. A total of 108 hospital pharmacists across Australia responded to the questionnaire, and of these, 105 (97.2%) were collected electronically. The majority of respondents were female (80.2%), with median duration of practice of 7.5 years (IQR: 3.0-15.0) ( Table 1) .
Over 90% of hospital pharmacists agreed that they had an important role in managing statin therapy in older inpatients (95% CI: 90.5-98.8%), and in providing advice to doctors regarding the initiation, continuation or cessation of statins in particular indications (95% CI: 86.9-97.6%) (Figure 1 ). Less than 40% of pharmacists agreed that most older patients are prescribed statins in accordance with clinical guidelines (95% CI: 27.4-47.6%), with most pharmacists agreeing that cessation or deprescribing may be appropriate in some patients (97.0%, 95% CI: 94.0-100.0%). Sixty-four percent of Accredited pharmacists are those who have gained accreditation to complete Home Medicines Reviews (HMRs). HMRs are organised between a patient, their regular general practitioner and an accredited pharmacist, and involve a home visit to the patient by the accredited pharmacist to review their medications. Reports are generated by the accredited pharmacist for the general practitioner, and often highlight issues or medications that require further review.
pharmacists agreed that they felt confident in their ability to identify patients in whom statin therapy should be deprescribed (95% CI: 53.6-75.0%), and 51% regularly made recommendations about deprescribing in older adults (95% CI: 40.5-60.7%), and this was not dependent on years of practice (Spearman's Rho q = À0.132, p = 0.216 and q = 0.101, p = 0.342).
There was no correlation between years of practice and responses, except those with fewer years of experience being less likely to agree that their recommendations would be considered by doctors (q = À0.209, p = 0.047). Clinical/ward pharmacists and those with postgraduate degrees were more likely to agree that pharmacists had an important role in managing statin therapy in older inpatients (q = 0.043, p = 0.018).
Finally, over 90% (95% CI: 85.7-97.6%) agreed that there was a need for guidelines to aid deprescribing of statins in older adults, and this was consistent across all years of practice. Figure 1 Hospital pharmacists' responses regarding optimising statin therapy in older inpatients. Sixteen questionnaires (14.8%) were excluded from the final analyses as fewer than 7 of 13 Likert-scale questions were completed.
DISCUSSION
Our study findings suggest that the majority of pharmacists recognise their role in optimising statin therapy in older patients, including making recommendations to doctors, identifying adverse drug effects and providing advice to patients. Many felt that their recommendations would be accepted by doctors, yet only approximately half reported making regular recommendations about statin withdrawal. Studies have found that pharmacist-led interventions can reduce polypharmacy and inappropriate medication use. 6 A systematic review by Charrois et al. found that patients who had received pharmacist-led dyslipidaemia management and interventions in a primary care setting were more likely to receive changes in therapy to optimise their statin use. 7 However, current practice guidelines provide little decision support to practitioners and pharmacists in identifying individuals or population groups who may benefit from statin deprescribing interventions, as guidelines are currently limited to making recommendations on when to initiate therapy. 8 This was highlighted in a recent study, which identified the need for statin deprescribing guidelines as 1 of the top 5 deprescribing priorities for older patients. Interestingly, while all pharmacists in our study were aware of statin-related side effects such as diabetes, increased liver enzymes and myalgia, less than 40% were aware of potential side effects on cognitive impairment. Results from our study showed that over 90% of hospital pharmacists agreed that deprescribing in older patients may be appropriate but only 51% of hospital pharmacists regularly made recommendations about stopping statins in older inpatients. This suggests that there may be possible barriers to pharmacist-led deprescribing in hospital settings, such as organisational barriers involving multiple prescribers. 10 Our study was the first to capture hospital pharmacists' attitudes toward their role in optimising statin therapy in an acute care setting. We achieved a convenience sample of hospital pharmacists in Australia. However, self-selection of hospital pharmacists and a low response rate may introduce bias. Those who were more interested in the area may be more likely to respond, and as such, the results of our study may not be generalisable to all hospital pharmacists in Australia or other countries where the role of the hospital pharmacist may be different. The questionnaire was developed for use in this study and was not externally validated. In addition, our questionnaire adopted the Likert scale, which has the potential to reflect a degree of social desirability in respondents, where respondents consciously or unconsciously over-report 'good behaviour'. To minimise the effect of this bias on our results, the questionnaire was anonymous. Another limitation is that some of the questions may have been ambiguous (i.e. Question 7, confusion about separating statin effects on short vs long-term cognitive function, and Question 10, the use of words 'feel' and 'some').
As our study only looked at the perceptions of practising hospital pharmacists, it would be interesting to capture the view of community pharmacists and Home Medicines Review accredited pharmacists, who are wellpositioned to make clinical recommendations in primary care. Future studies should be conducted to examine how patients' perspectives (if and when elucidated) influence pharmacists' decisions in statin therapy management. Similarly, further exploration of the perceptions of patients and doctors regarding the role of pharmacists in statin therapy management may be able to inform and guide future studies exploring a pharmacist-led intervention.
CONCLUSION
Hospital pharmacists acknowledge they have a role in statin optimisation, including cessation of therapy when appropriate. However, the lack of evidence-based guidelines to support the deprescribing process, as well as other potential barriers including awareness of side effects, may act as a limitation to their potential role. Therefore, future studies should explore enablers and barriers to incorporating pharmacists into hospital deprescribing to aid in optimisation of pharmacological therapies.
